BioCentury | Aug 28, 2017
Politics & Policy

FDA steps up enforcement, regulation of stem cell therapies

...Friday, the U.S. Marshal Service raided StemImmune Inc. (San Diego, Calif) and its associated clinic California Stem Cell...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...cell marker receptor tyrosine kinase-like orphan receptor 1 (ROR1) Active Ph I ongoing Acquired companies California Stem Cell Inc....
BioCentury | Jan 28, 2016
Strategy

CIRM's endgame

...by 2020. CIRM was created with a $3 billion budget through the approval of the California Stem Cell...
BioCentury | Dec 16, 2014
Financial News

CIRM 2.0: New urgency for therapeutic development

...CIRM's internal science officers, outside experts, and at least one patient representative. Voters passed the California Stem Cell...
BioCentury | Oct 27, 2014
Company News

Rockefeller University, NeoStem deal

...relate to its dendritic cell/tumor cell technology, which NeoStem gained though its May acquisition of California Stem Cell Inc....
BioCentury | May 19, 2014
Company News

California Stem Cell, Cellular Biomedicine, NeoStem deal

...NeoStem completed its acquisition of stem cell company California Stem Cell for 5.3 million shares, or about $24.5...
...$24.5 million based on NeoStem's close of $4.59 on May 8, before the deal closed. California Stem Cell...
...payable in cash or shares (see BioCentury, April 21). Subsequently, NeoStem licensed technology acquired from California Stem Cell...
BioCentury | Apr 21, 2014
Company News

California Stem Cell, NeoStem deal

...NeoStem will acquire stem cell company California Stem Cell for 5.3 million shares, or about $34.1 million based...
...million based on NeoStem's close of $6.40 on April 11, before the deal was announced. California Stem Cell...
...melanoma, for which the product has Fast Track and Orphan Drug designation in the U.S. California Stem Cell...
BioCentury | Apr 7, 2014
Clinical News

Melapuldencel-T: Phase I data

...but declined to disclose a time frame for when the trial will start. In May, California Stem Cell...
...Cellular Biomedicine has an exclusive license from California Stem Cell to develop and commercialize TC-DC in China. California Stem Cell Inc....
BioCentury | Mar 20, 2014
Translation in Brief

Translational tidbits

...Lab to develop in vivo molecular imaging agents for cardiovascular and metabolic disease and cancer California Stem Cell Inc....
BioCentury | Feb 27, 2014
Tools & Techniques

(Pluri)potent acid

...The analytical net has to be broadened," said Parker. Hans Keirstead, president and CEO of California Stem Cell Inc....
...Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Brigham and Women's Hospital , Boston, Mass. California Stem Cell Inc....
Items per page:
1 - 10 of 39
BioCentury | Aug 28, 2017
Politics & Policy

FDA steps up enforcement, regulation of stem cell therapies

...Friday, the U.S. Marshal Service raided StemImmune Inc. (San Diego, Calif) and its associated clinic California Stem Cell...
BioCentury | May 11, 2017
Tools & Techniques

Stemming the tide

...cell marker receptor tyrosine kinase-like orphan receptor 1 (ROR1) Active Ph I ongoing Acquired companies California Stem Cell Inc....
BioCentury | Jan 28, 2016
Strategy

CIRM's endgame

...by 2020. CIRM was created with a $3 billion budget through the approval of the California Stem Cell...
BioCentury | Dec 16, 2014
Financial News

CIRM 2.0: New urgency for therapeutic development

...CIRM's internal science officers, outside experts, and at least one patient representative. Voters passed the California Stem Cell...
BioCentury | Oct 27, 2014
Company News

Rockefeller University, NeoStem deal

...relate to its dendritic cell/tumor cell technology, which NeoStem gained though its May acquisition of California Stem Cell Inc....
BioCentury | May 19, 2014
Company News

California Stem Cell, Cellular Biomedicine, NeoStem deal

...NeoStem completed its acquisition of stem cell company California Stem Cell for 5.3 million shares, or about $24.5...
...$24.5 million based on NeoStem's close of $4.59 on May 8, before the deal closed. California Stem Cell...
...payable in cash or shares (see BioCentury, April 21). Subsequently, NeoStem licensed technology acquired from California Stem Cell...
BioCentury | Apr 21, 2014
Company News

California Stem Cell, NeoStem deal

...NeoStem will acquire stem cell company California Stem Cell for 5.3 million shares, or about $34.1 million based...
...million based on NeoStem's close of $6.40 on April 11, before the deal was announced. California Stem Cell...
...melanoma, for which the product has Fast Track and Orphan Drug designation in the U.S. California Stem Cell...
BioCentury | Apr 7, 2014
Clinical News

Melapuldencel-T: Phase I data

...but declined to disclose a time frame for when the trial will start. In May, California Stem Cell...
...Cellular Biomedicine has an exclusive license from California Stem Cell to develop and commercialize TC-DC in China. California Stem Cell Inc....
BioCentury | Mar 20, 2014
Translation in Brief

Translational tidbits

...Lab to develop in vivo molecular imaging agents for cardiovascular and metabolic disease and cancer California Stem Cell Inc....
BioCentury | Feb 27, 2014
Tools & Techniques

(Pluri)potent acid

...The analytical net has to be broadened," said Parker. Hans Keirstead, president and CEO of California Stem Cell Inc....
...Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Brigham and Women's Hospital , Boston, Mass. California Stem Cell Inc....
Items per page:
1 - 10 of 39